Rheumatoid arthritis: Developing pharmacological therapies

Expert Opinion on Investigational Drugs

Volumn 11, Issue 7, 2002, Pages 927-935

  Misischia, Richard J ^a   Moreland, Larry W ^a  

^a NONE   (United States)

Author keywords

Anakinra; COX 2 inhibitors; Etanercept; IL 1; Infliximab; Integrin antagonists; Rheumatoid arthritis; TNF

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ALEFACEPT; ANGIOGENESIS INHIBITOR; ANTIRHEUMATIC AGENT; BUCINDOLOL; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; EFALIZUMAB; ETANERCEPT; ETORICOXIB; IBUPROFEN; INFLIXIMAB; INTEGRIN; INTEGRIN ANTAGONIST; INTERLEUKIN 1; MACROGOL; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROFECOXIB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR; ISOENZYME; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; NEW DRUG; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN;

ANGIOGENESIS; CHRONIC ARTHRITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DRUG EFFICACY; DRUG SAFETY; EDEMA; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HUMAN; HYPERTENSION; IMMUNE SYSTEM; INJECTION SITE; MORBIDITY; MORTALITY; NEUROTOXICITY; NONHUMAN; PEPTIC ULCER; PHARYNGITIS; PRURITUS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; ANIMAL; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM;

ANIMAL; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; CYCLOOXYGENASE INHIBITORS; DRUGS, INVESTIGATIONAL; HUMAN; IMMUNOGLOBULIN G; INTEGRINS; ISOENZYMES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE; RECEPTORS, INTERLEUKIN-1; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR; ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035986897     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.7.927     Document Type: Review

References (69)

1. Inhibitors of tumor necrosis factor for rheumatoid arthritis
2. Epidemiology of rheumatoid arthritis
3. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis
4. Cytokine expression in chronic inflammatory disease
5. Role of cytokines, acute-phase proteins, and chemokines in the progression of rheumatoid arthritis
6. Role of cytokines in rheumatoid arthritis
7. Structural features and biochemical properties of TNF-alpha converting enzyme (TACE)
8. Cytokines in autoimmunity
9. The two different receptors for tumor necrosis factor mediate distinct cellular responses
10. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis
11. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: Toxicity and dose finding trial in refractory rheumatoid arthritis
12. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
13. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
14. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor (p75)-Fc fusion protein
15. Etanercept therapy in rheumatoid arthritis. A randomised, controlled trial
16. Demyelinating and neurologic events reported in association with tumor necrosis factor-alpha antagonism: By what mechanisms could tumor necrosis factor-alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?
17. Demyelination occurring during antitumor necrosis factor alpha therapy for inflammatory arthritides
18. Drug-induced systemic lupus erythematosis
19. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis
20. Leukocytoclastic vasculitis due to etanercept
21. Etanercept and infliximab associated with cutaneous vasculitis
22. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha
23. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
24. Therapeutic efficacy of multiple intravenous infusions of anti-tumour necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
25. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concommitant methotrexate: A randomised Phase III trial
26. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2
27. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor-alpha: Findings in open-label and placebo-controlled trials
28. Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis
29. Preliminary results of early clinical trials with the fully human anti-TNF alpha monoclonal antibody D2E7
30. The Armada Trial: A double-blind placebo controlled trial of the fully human anti-TNF monoclonal antibody, adalimumab (D2E7), in patients with active RA on methotrexate (MTX)
31. Efficacy of the fully human anti-TNF antibody D2E7 in rheumatoid arthritis
32. Long-term treatment with the fully human anti-TNF antibody D2E7 slows radiographic disease progression in rheumatoid arthritis
33. Antiarthritic activity of soluble tumor necrosis factor receptor Type I forms in adjuvant arthritis: Correlation of plasma levels with efficacy
34. A Phase I study of PEGylated soluble tumor necrosis factor receptor Type I (PEG sTNF-RI[p55])in subjects with rheumatoid arthritis (RA)
35. Non-immunogenicity of a PEGylated soluble tumor necrosis factor receptor Type I (PEG sTNF-RI [p55])
36. Clinical implications of osteoarthritis and aging
37. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts
38. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2
39. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding and perforation: An overview of epidemiological studies published in the 1990s
40. Epidemiological assessment of the safety of conventional nonsteroidal anti-inflammatory drugs
41. Nonsteroidal anti-inflammatory drugs and acute renal failure in elderly persons
42. The clinical significance of inhibition of renal prostaglandin synthesis
43. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications
44. A randomised trial comparing the effect of rofecoxib, a cyclooxygenase-2 specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
45. Comparison of the effect of rofecoxib (a cyclooxyenase-2 inhibitor), ibuprofen, and placebo on the gastrointestinal mucosa of patients with osteoarthritis: A randomised, double-blind, placebo-controlled trial
46. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis
47. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis
48. Comparison of the cyclooxygenase-1 properties of nonsteroidal anti-inflammatory drugs (NSAIDS) and selective cyclooxygenase-2 inhibitors, using sensitive microsomal and platelet assays
49. Celebrex package insert
50. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis
51. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
52. Bextra package insert
53. Etoricoxib (MK-0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2
54. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor
55. Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2 specific inhibitors
56. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides
57. Cyclooxygenase inhibition and thrombogenicity
58. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen and naproxen on COX-2 versus COX-1 in healthy volunteers
59. Effects of nabumetone compared to naproxen on platelet aggregation in patients with rheumatoid arthritis
60. Different roles of tumor necrosis factor-alpha and interleukin-1 in murine streptococcal cell wall arthritis
61. Treatment of rheumatoid arthritis with interleukin-1 receptor antagonist
62. A multi-center, double-blind, dose-ranging, randomised, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: Radiologic progression Larsen scores
63. Treatment of rheumatoid arthritis in patients with interleukin-1 receptor antagonist: Radiographic assessment
64. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate
65. Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist
66. Target effector role of vascular endothelium in the inflammatory response: Insights from the clinical trial of anti-TNF alpha antibody in rheumatoid arthritis
67. Alpha(v)beta(3) Integrin antagonists as inhibitors of bone resorption
68. Interleukin-1beta-stimulated invasion of articular cartilage by rheumatoid synovial fibroblasts is inhibited by antibodies to specific integrin receptors and by collagenase inhibitors
69. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes